Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Publishing timestamp: 2024-06-10 07:53:11
Summary
Moderna's combination vaccine targeting Covid and flu was found to be more effective than existing standalone shots in a late-stage trial. The company plans to file for regulatory approval this summer and hopes to enter the market in 2025, potentially giving it a lead over rivals Pfizer and Novavax. The combination shot aims to simplify protection against respiratory viruses and reduce burden on the healthcare system.
Sentiment: POSITIVE
Tickers: PFE, NVAX, MRNA, BNTX,
Keywords: biotechnology, health care industry, business, pfizer inc, science, biotech and pharmaceuticals, novavax inc, business news, breaking news, pharmaceuticals, moderna inc,